StreetInsider.com News Articles

UBS Starts Jade Biosciences (JBIO) at Buy

Mon, 15 Jun 2026 03:01:12 -0400

UBS analyst Michael Yee initiates coverage on Jade Biosciences (NASDAQ: JBIO) with a Buy rating and a price target of $45.00.

The analyst comments: “We believe JBIO's lead program JADE101 could be a best-in-class drug in the $20B+ IgAN market and could have $3-4B in peak sales potential. Initial Phase I data from JADE101 (anti-APRIL mAb) shows deep reduction on the IgA biomarker which we think could translate to best-in-class efficacy for patients and with convenient quarterly every three months dosing potential. We think the IgAN market has room for multiple drugs to succeed and won't be a winner-takes-all market --

UBS Starts Jade Biosciences (JBIO) at Buy

Mon, 15 Jun 2026 03:01:12 -0400

UBS analyst Michael Yee initiates coverage on Jade Biosciences (NASDAQ: JBIO) with a Buy rating and a price target of $45.00.

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: CAIN CHRISTOPHER W.

Thu, 11 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260611/26636485.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: CAIN CHRISTOPHER W.

Thu, 11 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260611/26636485.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: DOBMEIER ERIC

Thu, 11 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260611/26636424.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: DOBMEIER ERIC

Thu, 11 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260611/26636424.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: Klein Lawrence Otto

Thu, 11 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260611/26636418.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: Klein Lawrence Otto

Thu, 11 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260611/26636418.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: Lavelle Erin

Thu, 11 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260611/26636333.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: Lavelle Erin

Thu, 11 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260611/26636333.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: Fairmount Funds Management LLC

Thu, 11 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260611/26636334.html

Form 4 Jade Biosciences, Inc. For: Jun 09 Filed by: Fairmount Funds Management LLC

Thu, 11 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260611/26636334.html

Form 8-K Jade Biosciences, Inc. For: Jun 08

Thu, 11 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260611/26636112.html

Form 8-K Jade Biosciences, Inc. For: Jun 08

Thu, 11 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260611/26636112.html

Form SCHEDULE 13D/A Jade Biosciences, Inc. Filed by: Fairmount Funds Management LLC

Tue, 09 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260609/26624912.html

Form SCHEDULE 13D/A Jade Biosciences, Inc. Filed by: Fairmount Funds Management LLC

Tue, 09 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260609/26624912.html

Form DEFA14A Jade Biosciences, Inc.

Fri, 05 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260605/26611168.html

Form DEFA14A Jade Biosciences, Inc.

Fri, 05 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260605/26611168.html

Jade Biosciences completes $172.5 million stock offering

Fri, 05 Jun 2026 16:01:16 -0400

Jade Biosciences Inc. (NASDAQ: JBIO) completed its public offering of 11.5 million common shares at $15.00 per share, generating gross proceeds of $172.5 million before fees and expenses. The biotechnology company sold all shares in the offering, which included 1.5 million additional shares purchased through the underwriters' full exercise of their over-allotment option.

The clinical-stage company develops therapies for autoimmune diseases and plans to use the net proceeds to fund clinical trials, preclinical studies, manufacturing, research and development activities, capital expenditures, working capital and general corporate purposes, according to a company statement.